Clinical Diagnosis of COVID-19: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis)

Three years ago, a study involving 1,757 patients was conducted to develop a clinical scoring system for diagnosing COVID-19, known as the AndroCoV Clinical Scoring. The aim was to create a diagnostic tool that was accurate, sensitive, easy to use, and did not require a rtPCR-SARS-CoV-2 test. The scoring system was based on the number of symptoms, presence of anosmia (loss of smell), and known positive household contact. The scoring system that required two or more symptoms, or anosmia or ageusia (loss of taste) alone, for subjects without known contact, or one or more symptoms, including anosmia or ageusia alone, when with known positive contacts, showed the highest accuracy (80.4%) and higher sensitivity (85.7%) than commercially available rtPCR-SARS-CoV-2 kit tests. The study concluded that the AndroCoV Clinical Scoring for COVID-19 Diagnosis was a feasible, easy, costless, and sensitive diagnostic tool for clinical diagnosis of COVID-19.